ABC008 for Inclusion Body Myositis
This trial is testing a new drug called ABC008 to help people with Inclusion Body Myositis, a muscle disease with few treatment options. The drug may work by affecting certain immune cells. Researchers will check if it improves muscle strength and quality of life.
Popular Filters
Trials for Myositis Patients
Monoclonal Antibodies
Efgartigimod SC for Myositis
This trial aims to check the safety and effectiveness of an injectable medication called efgartigimod PH20 SC in adults with muscle inflammation who participated in an earlier phase. The medication works by reducing harmful proteins that cause muscle problems.
Monoclonal Antibodies
Daxdilimab for Inflammatory Myositis
This trial is testing daxdilimab, a new medicine, to see if it can help patients with specific muscle and skin diseases by reducing inflammation and symptoms. The study focuses on patients with dermatomyositis or anti-synthetase inflammatory myositis.
Monoclonal Antibodies
Efgartigimod for Myositis
This trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Monoclonal Antibodies
Nipocalimab for Myositis
This trial is testing Nipocalimab, a medicine that blocks harmful antibodies, in patients with muscle weakness and other issues due to idiopathic inflammatory myopathies (IIM). The goal is to see if it can improve their condition by lowering harmful antibody levels.
Trials for PM Patients
Monoclonal Antibodies
Efgartigimod SC for Myositis
This trial aims to check the safety and effectiveness of an injectable medication called efgartigimod PH20 SC in adults with muscle inflammation who participated in an earlier phase. The medication works by reducing harmful proteins that cause muscle problems.
M5049 for Myositis
This trial is testing a pill called M5049 for people with muscle diseases known as dermatomyositis (DM) and polymyositis (PM). These conditions cause muscle inflammation and weakness. The pill aims to reduce inflammation and improve muscle strength over several months.
Monoclonal Antibodies
Efgartigimod for Myositis
This trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Monoclonal Antibodies
Nipocalimab for Myositis
This trial is testing Nipocalimab, a medicine that blocks harmful antibodies, in patients with muscle weakness and other issues due to idiopathic inflammatory myopathies (IIM). The goal is to see if it can improve their condition by lowering harmful antibody levels.
Phase 3 Trials
Monoclonal Antibodies
Efgartigimod SC for Myositis
This trial aims to check the safety and effectiveness of an injectable medication called efgartigimod PH20 SC in adults with muscle inflammation who participated in an earlier phase. The medication works by reducing harmful proteins that cause muscle problems.
Monoclonal Antibodies
Efgartigimod for Myositis
This trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
mTOR inhibitor
Sirolimus for Inclusion Body Myositis
This trial tests Sirolimus, a drug used in organ transplants, on patients with Inclusion Body Myositis (IBM). IBM causes muscle weakness, and current treatments are often ineffective. Sirolimus may help by calming harmful immune responses and cleaning up damaged proteins in muscle cells. Sirolimus has been used in organ transplant recipients to reduce the risk of skin cancer and manage immune system activity.
Trials With No Placebo
Monoclonal Antibodies
Efgartigimod SC for Myositis
This trial aims to check the safety and effectiveness of an injectable medication called efgartigimod PH20 SC in adults with muscle inflammation who participated in an earlier phase. The medication works by reducing harmful proteins that cause muscle problems.
Frequently Asked Questions
Introduction to polymyositis
What are the top hospitals conducting polymyositis research?
In the realm of clinical trials for polymyositis, several hospitals are making notable contributions to advance our understanding and treatment of this rare inflammatory muscle disease. In Upland, California, the Inland Rheumatology & Osteoporosis Medical Group is actively involved in a single trial focused on polymyositis. Although their all-time record stands at just one trial thus far, their dedication to researching this condition is evident as they recorded their first polymyositis trial in 2023.
Meanwhile, Omega Research Orlando located in Orlando also demonstrates its commitment to combating polymyositis with an ongoing clinical trial dedicated solely to this disease. Similarly having conducted only one previous study since recording its first polymyositis trial in 2023.
Across the country in Saint Louis, Missouri's Washington University School of Medicine has embarked on a profound journey of understanding and treating polymyositis through an active clinical trial while boasting two additional completed studies since starting their first investigation back in2017.
Moreover within Saint Louis itself another institution Washington University Pulmonary Function Laboratory joins forces by conducting a current polysomytits marked examination along with Arthritis and Rheumatology research Institute stationed at Allen not only contributes significantly through it's present health testing but also displays promising future collaboration wherein each facilitated specific exploration into Polymysotis providing necessary impetus for further medical advancements
Although these numbers may seem modest compared to other conditions or institutions' contributions; it is important to recognize that every step taken towards unraveling the complexities surrounding polymyositis brings us closer to improving outcomes for those affected by this challenging autoimmune disorder. The collective efforts of these hospitals highlight the determination and perseverance required for medical progress and serve as beacons of hope for patients worldwide.
Which are the best cities for polymyositis clinical trials?
When it comes to polymyositis clinical trials, certain cities show promise as hubs for research and development. Kansas City, Kansas has 3 active trials focused on studying PF-06823859 and other potential treatments. Orlando, Florida also stands out with 2 ongoing trials investigating PF-06823859 and Open Label Extension (OLE) Period: M5049 high dose among others. Saint Louis, Missouri, Glendale and Scottsdale in Arizona each have 2 active trials primarily examining the effectiveness of PF-06823859 alongside other potential interventions. These cities offer individuals with polymyositis access to cutting-edge clinical trials that could pave the way for improved treatment options and outcomes in the future.
Which are the top treatments for polymyositis being explored in clinical trials?
Polymyositis, a challenging condition, is currently being explored in clinical trials with some promising treatments that show potential. One such treatment is PF-06823859, which has one active trial and is the focus of one all-time polymyositis trial since it was first listed in 2023. Another hopeful avenue being investigated is the use of umbilical cord lining stem cells. This therapy has also shown promise with one active trial and one all-time polymyositis trial since its listing in 2021. These ongoing studies provide hope for those living with polymyositis, as researchers continue to strive towards effective treatments for this complex disease.
What are the most recent clinical trials for polymyositis?
Exciting advancements are being made in the clinical trials for polymyositis, offering hope to those affected by this condition. One notable trial is evaluating the effectiveness of PF-06823859, a potential treatment that has reached Phase 3. This promising drug could provide new options for managing and improving outcomes in polymyositis patients. Additionally, an ongoing Phase 2 trial involving high-dose M5049 is showing promise in its open-label extension period. These trials represent significant progress towards advancing our understanding and treatment of polymyositis, bringing us closer to better care and improved quality of life for individuals living with this disease.
What polymyositis clinical trials were recently completed?
A recent milestone in the field of polymyositis research was the completion of a clinical trial investigating KZR-616. Sponsored by Kezar Life Sciences, Inc., this trial concluded in November 2020. The findings from this study contribute to our understanding of potential treatments for polymyositis and offer hope for patients seeking effective therapies against this challenging condition.